DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 24, 2014, Pages 10917-10922

  Yuan, Sheng Guang ^a,b   Liao, Wei Jia ^a,b   Yang, Jian Jun ^a,b   Huang, Guo Jin ^a,b   Huang, Zhao Quan ^a,b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair   (China)

Author keywords

Biomarker; DEPDC1; Diagnosis; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; DEPDC1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MESSENGER RNA; TUMOR MARKER; TUMOR PROTEIN;

CANCER STAGING; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW UP; GENETICS; HUMAN; LIVER; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GTPASE-ACTIVATING PROTEINS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84923066030     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.24.10917     Document Type: Article

References (21)

1. Ballon DR, Flanary PL, Gladue DP, et al (2006). DEP-domain-mediated regulation of gpcr signaling responses. Cell, 126, 1079-93.
2. Cheng CH, Lee CF, Wu TH, et al (2011). Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol, 9, 114.
3. Ercolani G, Grazi GL, Ravaioli M, et al (2003). Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg, 237, 536-43.
4. Fazeli Z, Pourhoseingholi MA, Vahedi M, et al (2012). Burden of hepatocellular carcinoma in Asia. Asian Pac J Cancer Prev, 13, 5955-8.
5. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
6. Harada Y, Kanehira M, Fujisawa Y, et al (2010). Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res, 70, 5829-39.
7. Ji D, Lu Z-T, Li Y-Q, et al (2014). MACC1 Expression Correlates with PFKFB2 and Survival in Hepatocellular Carcinoma. Asian Pac J Cancer Prev, 15, 999-1003.
8. Kanehira M, Harada Y, Takata R, et al (2007). Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene, 26, 6448-55.
9. Kassambara A, Schoenhals M, Moreaux J, et al (2013). Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One, 8, 62752.
10. Kharrat A, Millevoi S, Baraldi E, et al (1998). Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries. Biochim Biophys Acta, 1385, 157-64.
11. Kobayashi A, Kawasaki S, Miyagawa S, et al (2006). Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma. Hepatogastroenterol, 53, 736-41.
12. Kretschmer C, Sterner-Kock A, Siedentopf F, et al (2011). Identification of early molecular markers for breast cancer. Mol Cancer, 10, 15.
13. Liao W, Liu W, Yuan Q, et al (2013). Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS One, 8, 80789.
14. Obara W, Ohsawa R, Kanehira M, et al (2012). Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol, 42, 591-600.
15. Okayama H, Kohno T, Ishii Y, et al (2012). Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res, 72, 100-11.
16. Peng SY, Chen WJ, Lai PL, et al (2004). High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer, 112, 44-50.
17. Sendoel A, Maida S, Zheng X, et al (2014). DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol, 16, 812-20.
18. Sokol S (2000). A role for Wnts in morpho-genesis and tissue polarity. Nat Cell Biol, 2, 124-5.
19. Tandon P, Garcia-Tsao G (2009). Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int, 29, 502-10.
20. Tralhao JG, Dagher I, Lino T, et al (2007). Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol, 33, 746-51.
21. Wang T, Hu HS, Feng YX, et al (2010). Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer, 102, 1618-26.